Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-20
DOI
10.1038/s41375-020-01018-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Coronavirus Infections—More Than Just the Common Cold
- (2020) Catharine I. Paules et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- On the use of corticosteroids for 2019-nCoV pneumonia
- (2020) Lianhan Shang et al. LANCET
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
- (2020) Clark D Russell et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial
- (2020) Jesús Villar et al. Lancet Respiratory Medicine
- Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
- (2020) Jean-Jacques Kiladjian et al. Lancet Haematology
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
- (2020) Paola Toniati et al. AUTOIMMUNITY REVIEWS
- COVID-19 and its implications for thrombosis and anticoagulation
- (2020) Jean Marie Connors et al. BLOOD
- An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19)
- (2020) Saibal Das et al. CLINICAL DRUG INVESTIGATION
- Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
- (2020) Valentina Morena et al. European Journal of Internal Medicine
- Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports
- (2020) Valeria Gaspari et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis
- (2020) Zhenwei Yang et al. JOURNAL OF INFECTION
- Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
- (2020) Marc Feldmann et al. LANCET
- COVID-19 and Italy: what next?
- (2020) Andrea Remuzzi et al. LANCET
- Endothelial cell infection and endotheliitis in COVID-19
- (2020) Zsuzsanna Varga et al. LANCET
- An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study
- (2020) Lucio Verdoni et al. LANCET
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
- (2020) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
- (2020) Maximilian Ackermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir — An Important First Step
- (2020) Raphael Dolin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
- (2020) Joshua Geleris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
- (2020) et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Conquest of COVID‐19. Publish it to death?
- (2020) Robert P. Gale BRITISH JOURNAL OF HAEMATOLOGY
- Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019
- (2020) Lisa K. Moores et al. CHEST
- Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
- (2020) Alessio Mazzoni et al. JOURNAL OF CLINICAL INVESTIGATION
- Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
- (2020) F. Heidel et al. LEUKEMIA
- Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
- (2020) Andreas Neubauer et al. LEUKEMIA
- Risk factors for death in 1859 subjects with COVID-19
- (2020) Lei Chen et al. LEUKEMIA
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
- (2020) F. La Rosée et al. LEUKEMIA
- Thrombosis risk associated with COVID-19 infection. A scoping review
- (2020) Fatimah Al-Ani et al. THROMBOSIS RESEARCH
- Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial
- (2019) Asra Ahmed et al. Lancet Haematology
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
- (2019) Andrea Cossarizza et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome
- (2014) Laurence Fardet et al. Arthritis & Rheumatology
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation
- (2010) Andreia Soares et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Cytokines and chemokines in follicular fluids and potential of the corresponding embryo: the role of granulocyte colony-stimulating factor
- (2008) N. Ledee et al. HUMAN REPRODUCTION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started